Form 4: RA Capital Boosts Stake in Mineralys Therapeutics

RA Capital Management and affiliated entities acquired over 1.1 million shares of Mineralys Therapeutics common stock for $25.5 per share.

Summary

• RA Capital Management, L.P., along with its affiliated funds RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P., acquired 1,176,470 shares of Mineralys Therapeutics, Inc. common stock.
• The acquisition occurred on September 4, 2025, at a price of $25.5 per share.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase.
• Following this transaction, RA Capital Healthcare Fund, L.P. indirectly beneficially owns 5,456,521 shares, and RA Capital Nexus Fund III, L.P. indirectly beneficially owns 1,867,229 shares.
• The total beneficial ownership by RA Capital entities and associated individuals (Peter Kolchinsky and Rajeev Shah) amounts to 7,323,750 shares.
• Dr. Derek DiRocco, a Partner of RA Capital Management, serves on Mineralys Therapeutics' board of directors.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a substantial insider purchase by a major institutional investor and director-affiliated entities, signaling strong confidence in the company's future.

Positives

• Significant insider buying by a major institutional investor and director-affiliated entities signals strong confidence in the company's future prospects.
• The purchase was made at a substantial price of $25.5 per share, indicating a belief in the stock's value at or above this level.
• The transaction was conducted under a Rule 10b5-1(c) plan, suggesting a strategic, pre-planned investment rather than an opportunistic one.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company. However, the significant insider purchase by a major investor and director-affiliated entities implicitly signals a positive outlook on the company's future performance and valuation.

Management Comments

• RA Capital Management, L.P., RA Capital Management GP, LLC, RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund III, L.P., Dr. Peter Kolchinsky, and Mr. Rajeev Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Industry Context

In the biotechnology and pharmaceutical sectors, significant insider purchases by institutional investors, especially those with board representation, are often interpreted as a strong vote of confidence. This can signal positive expectations regarding upcoming clinical trial results, regulatory milestones, or commercialization prospects for the company's pipeline assets, which are critical value drivers in the industry.

Related Party Transactions

• The acquisition of common stock by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund III, L.P., and associated individuals (Peter Kolchinsky, Rajeev Shah), who are directors and 10% owners, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The significant insider purchase may instill greater confidence among existing shareholders and attract new investors, potentially leading to positive share price movement.
• Employees: A strong vote of confidence from major investors can positively impact employee morale and retention, especially in a development-stage biotech company.

Key Dates

Recommendation

The substantial insider purchase by RA Capital Management and its affiliates, who are significant shareholders and have board representation, at a price of $25.5 per share, indicates a strong belief in the company's intrinsic value and future growth potential. This action, especially when executed under a 10b5-1 plan, suggests a strategic and confident investment, making the stock a 'strong buy' for seasoned investors.

Keywords

Mineralys Therapeutics, MLYS, RA Capital Management, Insider Buying, Form 4, Biotechnology, Pharmaceuticals, Equity Acquisition, Institutional Investor, Director Ownership